

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
24 December 2003 (24.12.2003)

PCT

(10) International Publication Number
WO 03/105737 A1

(51) International Patent Classification⁷: **A61F 02/28**

(21) International Application Number: **PCT/US03/17444**

(22) International Filing Date: 4 June 2003 (04.06.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/388,639 14 June 2002 (14.06.2002) US

(71) Applicant (for all designated States except US): **CROSS-CART, INC. [US/US]; 3727 Buchanan Street, San Francisco, CA 94123 (US).**

(72) Inventor; and

(75) Inventor/Applicant (for US only): **STONE, Kevin, R. [US/US]; 1 Throckmorton Lane, Mill Valley, Ca 94941 (US).**

(74) Agent: **LAPPIN, Mark, G.; McDermott, Will & Emery, 28 State Street, Boston, MA 02109 (US).**

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



A1

WO 03/105737

(54) Title: **GALACTOSIDASE-TREATED PROSTHETIC DEVICES**

(57) Abstract: Matrix material for a substantially immunologically-compatible meniscal augmentation device of biocompatible and partially bioresorbable fibers is prepared by treatment with *α*-galactosidase to eliminate *α*-Gal epitopes. Upon implantation into a segmental defect of a meniscus, the composite of the meniscal augmentation device and the meniscus establishes a scaffold adapted for ingrowth of meniscal fibrochondrocytes.